In addition, our study also proposes a re-evaluation of STAT3 inhibitors46 as therapeutic strategies for any inflammatory or fibrotic disease or cancer, as inhibition of STAT3 in vivo might bear the risk of triggering malignant transformation of incipient pre-malignant cells harbouring KRAS mutations within the lung. This evidence concerns the gene STAT3 and cancer.